Why is "Nature Reviews Drug Discovery" trending?

Search Interest Perspective

• The changing landscape of medicinal chemistry optimization - Nature
• Induced proximity-based therapeutic modalities - Nature
• 2025 FDA approvals - Nature
• Targeting extrachromosomal DNA in human cancers - Nature
• RNA modification systems as therapeutic targets - Nature
• Synthetic lethality in cancer drug discovery: challenges and opportunities - Nature
• Therapeutic targeting of neuroimmune mechanisms in neurodegeneration - Nature
• RNA chemistry and therapeutics - Nature
• Triggering ferroptosis to tackle cancer - Nature
• Advances in the treatment of systemic lupus erythematosus - Nature
• Targeting protein disorder: the next hurdle in drug discovery - Nature
• Targeting the Hippo pathway in cancer - Nature
• Strategies to reduce the risks of mRNA drug and vaccine toxicity - Nature
• Modulating biomolecular condensates: a novel approach to drug discovery - Nature
• Targeting neutrophils for cancer therapy - Nature
• Tailor made: the art of therapeutic mRNA design - Nature
• Radiopharmaceutical therapy in cancer: clinical advances and challenges - Nature
• Applications of machine learning in drug discovery and development - Nature
• Targeting hypoxia-inducible factors: therapeutic opportunities and challenges - Nature
• Trends in clinical success rates - Nature
• mRNA-based therapeutics — developing a new class of drugs - Nature
• Diagnosing the decline in pharmaceutical R&D efficiency - Nature
• Identification of neoantigens for individualized therapeutic cancer vaccines - Nature
• A dynamic map for learning, communicating, navigating and improving therapeutic development - Nature
• The PROTACtable genome - Nature
• Targeting mitophagy in neurodegenerative diseases - Nature
• Drugging p53 in cancer: one protein, many targets - Nature
• Birgitte Volck - Nature
• Believe it or not: how much can we rely on published data on potential drug targets? - Nature
• Lessons from 60 years of pharmaceutical innovation - Nature
• The hepatocellular carcinoma market - Nature
• Rethinking drug design in the artificial intelligence era - Nature
• mRNA vaccines for infectious diseases: principles, delivery and clinical translation - Nature
• Extracellular vesicles: biology and emerging therapeutic opportunities - Nature
• RNAi-based drug design: considerations and future directions - Nature
• Antimalarial drug discovery: progress and approaches - Nature
• Targeting RNA structures with small molecules - Nature
• Advances in oligonucleotide drug delivery - Nature
• Richard D. Klausner - Nature
• Phase II failures: 2008–2010 - Nature
• Organs-on-chips: into the next decade - Nature
• A faster way to happiness - Nature
• Pulling away from the pack in drug launches - Nature
• Monoclonal antibodies market - Nature
• From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity - Nature
• Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH) - Nature
• Pharmaceutical forecasting: throwing darts? - Nature
• Deuterated drugs draw heavier backing - Nature
• Recent advances with liposomes as pharmaceutical carriers - Nature
• Penny Heaton - Nature
• Zebrafish as tools for drug discovery - Nature
• Monoclonal antibody biosimilars - Nature
• Bispecific antibodies: a mechanistic review of the pipeline - Nature
• Integrins as therapeutic targets: lessons and opportunities - Nature
• Anti-obesity drug discovery: advances and challenges - Nature
• Fragment-based phenotypic screening is a hit - Nature
• PROTAC targeted protein degraders: the past is prologue - Nature
• How much do clinical trials cost? - Nature
• Engineering living therapeutics with synthetic biology - Nature
• The safety and side effects of monoclonal antibodies - Nature
• Engineering precision nanoparticles for drug delivery - Nature
• Cardiology and vascular disoders - Nature
• Antibody–drug conjugates come of age in oncology - Nature
• Drugging the undruggable RAS: Mission Possible? - Nature
• Phase II and phase III failures: 2013–2015 - Nature
• The role of ligand efficiency metrics in drug discovery - Nature
• Impact of high-throughput screening in biomedical research - Nature
• Accelerating antiviral drug discovery: lessons from COVID-19 - Nature
• The COVID-19 vaccine development landscape - Nature
• Do you want chips with that? - Nature
• Phase III and submission failures: 2007–2010 - Nature
• Artificial intelligence for natural product drug discovery - Nature
• Deuterium in drug discovery: progress, opportunities and challenges - Nature
• RAS-targeted therapies: is the undruggable drugged? - Nature
• Reconnecting the brain after injury - Nature
• Parsing clinical success rates - Nature
• The multiple sclerosis market - Nature
• Burgeoning oncology pipeline raises questions about sustainability - Nature
• Delivery technologies for cancer immunotherapy - Nature
• Averting panic attacks - Nature
• Nanoparticle therapeutics: an emerging treatment modality for cancer - Nature
• Microglia-targeted candidates push the Alzheimer drug envelope - Nature
• George Yancopoulos - Nature
• Thirty years of NRF2: advances and therapeutic challenges - Nature
• Landscape for medical countermeasure development - Nature
• A class of its own - Nature
• Specificity concerns with antibodies for receptor mapping - Nature
• Can the pharmaceutical industry reduce attrition rates? - Nature
• Sequential immunotherapy: towards cures for autoimmunity - Nature
• The quest to slow ageing through drug discovery - Nature
• Michael Rosenblatt - Nature
• Can you trust your animal study data? - Nature
• Eric S. Lander - Nature
• Drug discovery in China - Nature
• Zeroing in on neurodegenerative α-synuclein - Nature
• Tadataka Yamada - Nature
• Margaret Anderson - Nature
• Anthony Fauci - Nature
• Jean-Jacques Garaud - Nature
• NCATS launches 'periodic table' for medicinal product ingredients - Nature